^
    CANCER:

    Childhood B Acute Lymphoblastic Leukemia





    Show legend
    Group by Gene:
    Include preclinical:

    0
    CD19-targeted CAR-T immunotherapy
    tisagenlecleucel-T
    1
    Proteasome inhibitor
    bortezomib
    2
    Multi-tyrosine kinase inhibitor
    nintedanib
    3
    Proteasome inhibitor, CD20 inhibitor
    rituximab + bortezomib
    4
    CD20 inhibitor
    rituximab
    5
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    6
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    7
    CD19 inhibitor, CD3 agonist
    blinatumomab
    8
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    9
    Topoisomerase II inhibitor, Tubulin polymerization inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter
    vincristine + mitoxantrone + pegaspargase
    10
    THF dehydrogenase inhibitor, Alkylating agent, Tubulin polymerization inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor, Aspartate-ammonia ligase inhibitor, Asparagine depleter
    cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
    11
    Aspartate-ammonia ligase inhibitor, Asparagine depleter
    calaspargase pegol-mknl
    12
    Topoisomerase II inhibitor, Alkylating agent, DNA inhibitor, DNA synthesis inhibitor
    cyclophosphamide + etoposide oral + nelarabine
    cyclophosphamide + etoposide oral + clofarabine
    13
    CD123-targeted antibody-drug conjugate, DNA replication inhibitor
    IMGN632
    14
    SYK inhibitor
    GS-9973
    15
    HER2 inhibitor
    trastuzumab
    16
    AKT inhibitor
    MK-2206
    17
    CD9 inhibitor
    KBA1412
    18
    Alkylating agent
    cyclophosphamide
    19
    Menin-MLL inhibitor
    DS-1594
    No biomarker
    JAK2 fusion
    ABL2 fusion
    IL7R mutation
    SH2B3 alteration
    CRLF2 rearrangement + JAK2 fusion
    EPOR rearrangement
    ABL1 fusion
    CD20 expression
    CD20 positive
    PDGFRB fusion
    KMT2A rearrangement
    PAX5 fusion
    IL3RA expression
    KRAS mutation
    NRAS mutation
    HER-2 expression
    SNX2-ABL1 fusion
    MLL rearrangement
    CD9 expression
    FOXO1 underexpression
    IGH-CRLF2 fusion + JAK2 R867Q
    JAK1 S646F
    IGH-CRLF2 fusion
    IGH-CRLF2 fusion + JAK2 GPInsR683
    P2RY8-CRLF2 fusion + JAK2 QGinsR683
    EBF1-PDGFRB fusion